UNSPSC 51142546: Bromocriptine mesilate or mesylate

This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFP983J3OD, chemically known as 2-bromo-alpha-ergocryptine, methanesulfonate but more generally known as bromocriptine mesilate, which bears US NIH Compound Identifier 31100. European Medicines Agency schedules Bromocriptine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00878MIG.

UNSPSC 51142546 Bromocriptine mesilate or mesylate is a Commodity code. The nominal scope—a single pharmaceutical active ingredient—does not align with recent state and local procurement activity tagged under this code. The three most recent opportunities involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical supply agreements, none of which center on bromocriptine mesilate specifically. State and local governments use pharmaceutical codes in this family to solicit raw materials, finished goods, and supply-chain services across a wide range of medication types; the tagging appears to reflect broader pharmaceutical procurement categories rather than the specific active pharmaceutical ingredient named in the code itself.

The issuing bodies include county health agencies, state health and human services commissions, and cooperative purchasing alliances that represent multi-state municipal and county participation. Recent opportunities originated from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across Minnesota, Oregon, and subordinate jurisdictions. Activity spans the Southeast, Southwest, and Upper Midwest. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2026), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (closed April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and performance beginning July 1, 2026. Given the mismatch between the code's nominal scope and actual procurement activity, vendors targeting this code should expect broad pharmaceutical supply solicitations rather than opportunities centered on bromocriptine mesilate alone.